Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

08 mars 2016 07h00 HE | Source: Curis, Inc.

Curis to Present at the 28th Annual Roth Conference

LEXINGTON, Mass., March 08, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
01 mars 2016 07h00 HE | Source: Curis, Inc.

Curis to Present at the Cowen and Company 36th Annual Health Care Conference

LEXINGTON, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
29 févr. 2016 07h00 HE | Source: Curis, Inc.

Curis Reports Fourth Quarter and Year-End 2015 Financial Results

LEXINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
22 févr. 2016 07h00 HE | Source: Curis, Inc.

Curis to Release Fourth Quarter and Year End 2015 Financial Results and Hold Conference Call on February 29, 2016

LEXINGTON, Mass., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
17 févr. 2016 07h00 HE | Source: Curis, Inc.

Curis to Present at the 2016 RBC Capital Markets Global Healthcare Conference

LEXINGTON, Mass., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
01 févr. 2016 16h05 HE | Source: Curis, Inc.

Curis to Present at the BIO CEO & Investor Conference

LEXINGTON, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
06 déc. 2015 13h15 HE | Source: Curis, Inc.

Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting

CUDC-907 (HDAC and PI3K inhibitor) demonstrates objective responses, including complete responses, in patients with relapsed/ refractory DLBCL with MYC alterations Curis expects to initiate a...
02 déc. 2015 07h00 HE | Source: Curis, Inc.

Curis to Present at the Oppenheimer 26th Annual Healthcare Conference

LEXINGTON, Mass., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
09 nov. 2015 07h00 HE | Source: Curis, Inc.

Curis Reports Third Quarter 2015 Financial Results

LEXINGTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
08 nov. 2015 12h30 HE | Source: Curis, Inc.

Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule PD-L1/VISTA and IRAK4 Programs at AACR-NCI-EORTC International Conference

LEXINGTON, Mass., Nov. 8, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...

Page précédente

Page suivante